

509,074

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



22 SEP 2004



(43) International Publication Date  
2 October 2003 (02.10.2003)

PCT

(10) International Publication Number  
WO 03/080624 A2

(51) International Patent Classification<sup>7</sup>: C07D 495/04,  
519/00, A61K 31/407, A61P 35/00

5551 Molina Road, North Vancouver, British Columbia  
V7R 4P3 (CA).

(21) International Application Number: PCT/CA03/00380

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 18 March 2003 (18.03.2003)

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

Published:

(26) Publication Language: English

— without international search report and to be republished  
upon receipt of that report

(30) Priority Data:

60/367,265 26 March 2002 (26.03.2002) US  
60/418,698 17 October 2002 (17.10.2002) US

(71) Applicant (*for all designated States except US*):

WELICHEM BIOTECH INC. [CA/CA]; 316-4475  
Wayburne Drive, Burnaby, British Columbia V5G 3L1  
(CA).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): CHEN, Genhui  
[CA/CA]; 4573 Frances, Burnaby, British Columbia  
V5C 2R6 (CA). LI, Bin [CN/CA]; 4720 Pandora Street,  
Burnaby, British Columbia V5C 2C3 (CA). LI, Jianxiong  
[CA/CA]; 117 Buckingham Drive, Port Moody, British  
Columbia V3H 2T4 (CA). WEBSTER, John [CA/CA];

WO 03/080624 A2

(54) Title: NOVEL DITHIOLPYRROLONES WITH THERAPEUTIC ACTIVITY

(57) Abstract: The present invention provides novel dithiopyrrolone compounds and their salts, which are useful as treatments for cancer and other proliferative diseases. The present invention also provides therapeutic compositions comprising particularly useful types of dithiopyrrolones, the salts thereof, and methods of using the compounds within such types, particularly in treating proliferative diseases such as cancer.

**NOVEL DITHIOLOPYRROLONES WITH THERAPEUTIC ACTIVITY****DESCRIPTION OF THE INVENTION**

The present invention provides novel dithiolopyrrolone compounds and their salts, which 5 are useful as treatments for cancer and other proliferative diseases. The present invention also provides therapeutic compositions comprising particularly useful types of dithiolopyrrolones, the salts thereof, and methods of using the compounds within such types, particularly in treating proliferative diseases such as cancer.

**10 BACKGROUND OF THE INVENTION**

Cancer is one of the major causes of death in humans and animals. Millions of people in the world are diagnosed every year as having cancer and a large proportion of these people die of cancer. Despite extensive worldwide effort over many years, cancers continue to be hard-to-treat diseases, and there is an urgent need for more effective anticancer drugs.

15 Dithiolopyrrolones are a group of compounds with 1,2-dithiolof[4,3-b]pyrrol-5(4H)-one ring. The substitutes attached to the ring, particularly at position 2 and 6, lead to diverse subgroups of derivatives with different structural features and bioactivities. Compounds bearing this basic structural feature have been known in the art. Natural dithiolopyrrolones have been shown to have activities against micro-organisms as well as other activities such as chemopreventive (Sharma *et al.*, 1994) and anticancer (US6020360, WO 99/12543 both of Webster *et. al.*). Certain synthetic 20 dithiolopyrrolones and their antimicrobial activities have been disclosed (D.S. Bhate & Y. M. Sambray, 1963. Hindustan, *Antibiotic Bulletin* 6(1): 17-18; Katsuaki Hagio *et al.* *Bull. Chem. Soc. Jpn* 1974, 47, 1484-1489; Broom, *et al.* WO 9505384 and Godfrey & Dell, GB2170498).

25 The present invention relates to certain new types of dithiolopyrrolones and particular specific dithiolopyrrolones which have been found to have particular use in the treatment of cancers. The invention relates to such types and particular compounds as new chemical compounds, and also to pharmaceutical compositions containing them and methods for the treatment of disease using them.

30 In addition, and more generally, such types of dithiolopyrrolones and particular specific dithiolopyrrolones are found to be useful against proliferative diseases in general. Proliferative diseases are, but are not limited to, disorders wherein unwanted cell proliferation of one or more subset(s) of cells in a multicellular organism occurs, resulting in harm (e.g., discomfort or decreased life expectancy) to the multicellular organism. Proliferative diseases can occur in different types of animals and in humans. Proliferative diseases include leukemia and blood vessel 35 proliferative disorders, and fibrotic disorders such as cancers, tumors, hyperplasias, fibrosis


(especially pulmonary fibrosis, but also other kinds of fibrosis, such as renal fibrosis), angiogenesis, psoriasis, atherosclerosis and smooth muscle cell proliferation in the blood vessels, such as stenosis or restenosis following angioplasty.

## 5 SUMMARY OF THE INVENTION

In one aspect the invention provides methods and compositions for treating proliferative diseases, such as cancer and psoriasis, comprising administrating to a subject in need of such treatment, an effective amount of a compound of one of the structures shown below: In another aspect, the invention deals with pharmaceutical compositions containing compounds of the 10 structures shown below, for the treatment of proliferative diseases, and especially cancer. In another aspect, the invention includes, as new chemical compounds, those compounds of the structures shown below are not previously disclosed.

The structures of compounds according to the invention are the following:

### (a). Compounds of the following formula (formula I)



15


wherein Z = aryl, heterocyclic, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl group, while X and the same Y can be the same or different, are hydrogen, substituted or unsubstituted alkyl, cycloalkyl, aryl, aralkyl or heterocyclic group, except the chemicals with:

Z = phenyl, Y = H, X = H, methyl, benzyl and Z = 4-pyridine, X = methyl, Y = H; or

20 wherein X = aryl, heterocyclic, Y and Z, can be the same or different, are hydrogen, unsubstituted or substituted or alkyl of two or less hydroxyl groups and no carboxylic acid group, cycloalkyl, aryl, aralkyl or heterocyclic group, except the chemicals with:

Z = methyl, Y = H, X = phenyl, 4-methoxyphenyl, 4-methylphenyl.


### (b) Compounds of the following formula (formula II)



25

wherein X, Y and Z can be the same or different, is hydrogen, substituted or unsubstituted alkyl, cycloalkyl, aryl, aralkyl or heterocyclic group, except that when X = Y = Z = methyl and when X = H, Y = Z = methyl.

In particular, the following group of compounds that are of the above (a):



wherein X and Y can be the same or different, are hydrogen, substituted or unsubstituted alkyl, cycloalkyl, aryl or aralkyl group. Z<sub>1</sub> is a group with at least two hydrophilic atoms selected from N or O, such as piperazinyl, 4-methyl-piperazinyl and morpholinyl. The position of -CH<sub>2</sub>-Z group can be at *ortho*, *meso* or *para* on the benzene ring.

10 In this disclosure, dithiopyrrolones within the Formulae I, II and III are referred to as "types of dithiopyrrolones" according to the invention or by similar wording, and individual compounds disclosed herein are referred to by the wording "specific dithiopyrrolones", "specific compounds", "particular compounds" or "compounds of the invention" or by similar wording.

15 DETAILED DESCRIPTION OF THE INVENTION

In this invention, it is discovered that different substitutes have great, unpredictable effects on the overall anticancer properties of different dithiopyrrolones. It was discovered that introduction of water-soluble groups, such as carboxyl group, polyhydroxyl groups (such as a sugar unit) drastically reduced the anticancer activity of the corresponding, unsubstituted compounds.

20 However, another newly designed group of compounds, together with the introduction of water-soluble groups, have not only significantly improved solubility in water, but surprisingly, they provide enhanced anticancer activity of the corresponding, unsubstituted compounds. This unexpected discovery is described in this invention, and allows us to invent different types of dithiopyrrolones.

25 The types of dithiopyrrolones and specific dithiopyrrolones of the subject invention are prepared by the methods described below together with the structure of each dithiopyrrolone compound for which structural information is given and has been confirmed by its NMR and MS spectroscopy.

Skilled chemists will be able to use procedures as disclosed herein and others to produce these types of dithioliopyrrolones and specific dithioliopyrrolones from commercially available stock substances. In carrying out such operations, any suitable filtration, chromatographic, and other purification techniques might be employed by those skilled in the art. A more complete 5 understanding of the invention can be obtained by reference to preferred embodiments of the invention, which are illustrated by the following specific examples and methods of the invention. It will be apparent to those skilled in the art that the examples involve use of materials and reagents that are commercially available from chemical companies, so no details are given respecting them.

Dithioliopyrrolones form salts, therefore, the compounds of the invention and types of 10 dithioliopyrrolones of the invention include the salts of the compounds disclosed herein and the types of dithioliopyrrolones disclosed herein. The term "salts", as used herein, denotes acidic and/or basic salts, formed with inorganic and/or organic acids and bases. Suitable acids include, for example, hydrochloric, sulfuric, nitric, benzenesulfonic, acetic, maleic, tartaric and the like, which are pharmaceutically acceptable. While pharmaceutically acceptable salts are preferred, particularly 15 when employing the compounds of the invention as medicaments, other salts find utility, for example, in the production of these compounds, or where non-medicament-type uses are contemplated.

The types of dithioliopyrrolones and the particular compounds disclosed herein have strong 20 antiproliferative activity, in particular, strong activity against a wide range of human cancer cell lines and especially in the treatment of malignant mammary cells. Importantly, they inhibit the growth of leukemia, lung, melanoma, colon, CSN, renal, prostate, ovarian and breast cancer cell 25 lines. They are also useful against other proliferative diseases, including blood vessel proliferative disorders, and fibrotic disorders such as cancers, tumors, hyperplasias, fibrosis (espeically pulmonary fibrosis, but also other kinds of fibrosis, such as renal fibrosis), angiogenesis, psoriasis, atherosclerosis and smooth muscle cell proliferation in the blood vessels, such as stenosis or restenosis following angioplasty.

The present invention provides methods of treating a mammal affected by cancers or other 30 proliferative diseases sensitive to the particular compounds and types of dithioliopyrrolones, which comprises administering to the affected individual a therapeutically effective amount of one of the specific compounds or a compound selected from the disclosed types of dithioliopyrrolones, a salt thereof or a pharmaceutical composition thereof. In particular, the compounds and the salts thereof of the invention may be used to treat mammalian cancers, and other proliferative diseases. The present invention also relates to the pharmaceutical compositions which contain an active ingredient of these compounds or a pharmaceutically acceptable salt thereof, or a compound or

pharmaceutically acceptable salt selected from a type of dithiopyrrolone of the invention, as well as the process for the preparation of such a pharmaceutical composition.

Examples of pharmaceutical compositions include any solid (tablets, pills, capsules, granules, powder etc.) or liquid (solutions, suspensions or emulsions) in a suitable composition for 5 oral, topical or parenteral administration. These formulations may contain the pure compound or be in combination with a carrier or some other pharmaceutically active compound. These compositions may need to be sterile when administered parenterally.

The administration of the disclosed compounds of the invention and of the disclosed types of dithiopyrrolones, and their pharmacologically active and physiologically compatible 10 derivatives, is useful for treating animals or humans that have, for example, leukemia, melanoma, cancers of the lung, colon, CSN, kidney, prostate, ovary, breast and the like using the accepted protocols of the National Cancer Institute (NCI). The dosage administered will be dependent upon the identity of the cancer or proliferative disease; the type of host involved including its age, health and weight; the kind of concurrent treatment, if any; and the frequency of treatment and therapeutic 15 ratio. Illustratively, dosage levels of the administered active ingredients are intravenous, 0.1 to about 200 mg/kg; intramuscular, 1 to about 500 mg/kg; orally, 1 to about 1000 mg/kg; intranasal instillation, 1 to about 1000 mg/kg; and aerosol, 1 to about 1000 mg/kg of host body weight. Expressed in terms of concentration, an active ingredient can be present in the compositions of the present invention for localized use about the cutis, intranasally, pharyngolaryngeally, bronchially, 20 bronchiolally, intravaginally, rectally, or ocularly in a concentration from about 0.01 to about 50% w/w of the composition; preferably about 1 to about 20% w/w of the composition; and for parenteral use in a concentration of from about 0.05 to about 50% w/v of the composition and preferably from about 5 to about 20% w/v. The disclosed specific compounds and types of 25 dithiopyrrolones, used as active ingredients to be employed as anticancer agents and antiproliferative agents, can be easily prepared in such unit dosage form with the employment of pharmaceutical materials which themselves are available in the art and can be prepared by established procedures.

In alternative aspects of the invention, the compounds of the invention may be used in treatments for cancers susceptible to such compounds, including both primary and metastatic solid 30 tumors, including carcinomas of breast, colon, rectum, lung, oropharynx, hypopharynx, esophagus, stomach, pancreas, liver, gallbladder and bile ducts, small intestine, urinary tract (including kidney, bladder and urothelium), female genital tract, (including cervix, uterus, and ovaries as well as choriocarcinoma and gestational trophoblastic disease), male genital tract (including prostate, seminal vesicles, testes and germ cell tumors), endocrine glands (including the thyroid, adrenal, and 35 pituitary glands), and skin, as well as hemangiomas, melanomas, sarcomas (including those arising

from bone and soft tissues as well as Kaposi's sarcoma) and tumors of the brain, nerves, eyes, and meninges (including astrocytomas, gliomas, glioblastomas, retinoblastomas, neuromas, neuroblastomas, Schwannomas, and meningiomas).

5 In some aspects of the invention, the types of dithioliopyrrolones and compounds of the invention are useful in treating proliferative diseases arising from hematopoietic malignancies such as leukemias (i.e. chloromas, plasmacytomas and the plaques and tumors of mycosis fungoides and cutaneous T-cell lymphomaileukemia) as well as in the treatment of lymphomas (both Hodgkin's and non-Hodgkin's lymphomas). In addition, the types of dithioliopyrrolone and compounds of the invention are useful in the prevention of metastases from the tumors described above either when 10 used alone or in combination with radiotherapy and/or other chemotherapeutic agents.

15 In some aspects of the invention, the types of dithioliopyrrolone and the compounds of the invention are useful in treating other proliferative diseases such as blood vessel proliferative disorders, and fibrotic disorders such as cancers, tumors, hyperplasias, fibrosis (especially pulmonary fibrosis, but also other kinds of fibrosis, such as renal fibrosis), angiogenesis, psoriasis, atherosclerosis and smooth muscle cell proliferation in the blood vessels, such as stenosis or restenosis following angioplasty and skin proliferative diseases, such as psoriasis.

#### EXAMPLE 1

20 The antiproliferative activity of a particular dithioliopyrrolone can be demonstrated by standard assays. These assays are commonly used by those skilled in the art and are accepted as indicative of antiproliferative activity in mammals. The antiproliferative activities of the compounds of the invention have been determined in cell cultures of human ovarian cancer, using a standard anti-proliferative test of the US National Cancer Institute (NCI). [ Monks, A. *et al.*, *J. Natl. Cancer Inst.* 83(11): 757-766, 1991].

25 The compounds in this example are species of Formula I which show superior antiproliferative activity against proliferative ovarian cancer Ovcar-3 cell line (Table 1) in comparison with a dithioliopyrrolone, XN3 that was disclosed in US 6020360 and WO 99012543 with anti-proliferative activities. The result showed that these novel dithioliopyrrolones have much stronger anti-proliferative activity than does XN3. The novel compound had activity against 56 30 cancer cell lines of a wide range of major cancers. (Table 1a).

Table 1a. Antiproliferative activity of novel compounds in comparison of XN3 against ovarian cancer cells, Ovar-3.

Compounds	IC <sub>50</sub> (μM)
BLI-093 (BLI093)	0.054

0037 (JS-02)	0.071
0038 (JS-03)	0.068
0058 (JS-38)	0.034
WBL-007 (WBI007)	0.028
WBL-018	0.070
R3 (WBL-R3)	0.078
R4 (WBL-R4)	0.046
XN3	0.22

Table 1a. Anti-proliferative activity of the novel compound 0058(JS-38) against 56 cancer cell lines.

PROLIFERATIVE CELLS	IC <sub>50</sub> (μM)
<b>Leukemia</b>	
CCRF-CEM	0.01<
HL-60(TB)	0.019
K-562	0.019
MOLT-4	0.15
RPMI-8226	0.01<
SR	0.02
<b>Non-Small Cell Lung Cancer</b>	
A549/ATCC	0.42
EKVX	0.13
HOP-62	0.13
HOP-92	0.18
NCI-H226	0.27
NCI-H23	0.21
NCI-H322M	8.56
NCI-H460	0.26
NCI-H522	0.19
<b>Colon Cancer</b>	
COLO 205	0.15
HCC-2998	0.11
HCT-116	0.016
HCT-15	0.02
HT29	0.05
KM12	2.97
SW-620	0.034
<b>CNS Cancer</b>	
SF-268	0.14
SF-295	0.23
SF-539	0.18
SNB-19	0.23
U251	0.15
<b>Melanoma</b>	

LOX IMVI	0.014
MALME-3M	0.19
M14	0.24
SK-MEL-2	0.18
SK-MEL-28	0.016
SK-MEL-5	0.12
UACC-257	0.15
UACC-62	0.19
<b>Ovarian Cancer</b>	
IGROV1	0.17
OVCAR-3	0.03
OVCAR-5	0.45
OVCAR-8	0.17
<b>Renal Cancer</b>	
786-0	0.06
A498	0.19
ACHN	0.14
CAKI-1	0.44
RXF 393	0.04
SN12C	0.12
TK-10	1.37
UO-31	0.20
<b>Prostate Cancer</b>	
PC-3	0.04
DU-145	0.013
<b>Breast Cancer</b>	
MCF7	0.17
NCI/ADR-RES	1.04
MDA-MB-231/ATCC	0.13
HS 578T	0.22
MDA-MB-435	0.22
BT-549	0.15
T-47D	0.013

## EXAMPLE 2

Compounds shown in Table 2 were tested against cancer cell line H460 as set forth in Example 1, results showed that the ant-proliferative activity varied widely among derivatives with different modifications of the base dithioliopyrrolone structure.

5


Table 2. Anti-proliferative activity of compounds together with other dithioliopyrrolones against cancer cell lines H460 and LCC6.

Compoud	IC <sub>50</sub> ( $\mu$ M)
	H460
0024	0.26
0066	<0.01
0068	<0.01
0069	0.04
WBI-4	<0.01

WBI-5	<0.01
WBI-6	0.046
0136	0.092
BLI-031-2	>50
0044	>1
JS-26	>1

## EXAMPLE 3

The compounds of the present invention are prepared according to the following synthetic scheme (Scheme 1):



Scheme 1

Intermediates prepared according to the above synthetic scheme (Scheme 1) procedure and used for the subsequent syntheses are listed in the following table.

Intermediate	X	Y	Z
1 and 2	a	2,4-dimethoxyphenyl	
	b	1-ethylpyrazole-5-yl	
	c	3,4,5-trimethoxyphenyl	
	d	benzyl	
	e	phenyl	
	f	4-methylphenyl	
	g	4-methoxyphenyl	
	h	4-isobutylphenyl	
	i	4-isopropylphenyl	

	j	methyl		
3	a	2,4-dimethoxyphenyl	H	
	b	1-ethylpyrazole-5-yl	H	
	c	3,4,5-trimethoxyphenyl	H	
	d	benzyl	H	
	e	phenyl	H	
	f	4-methylphenyl	H	
	g	4-methoxyphenyl	H	
	h	4-isobutylphenyl	H	
	i	4-isopropylphenyl	H	
	j	methyl	H	
	k	H	H	
	l	4-methoxyphenyl	benzyl-	
	m	4-hydroxyphenyl	benzyl-	
	n	2,4-dimethoxyphenyl	methyl	
4	a	2,4-dimethoxyphenyl	H	acetyl
	b	2,4-dimethoxyphenyl	H	nicotinoyl
	c	2,4-dimethoxyphenyl	H	trifluoroacetyl
	d	2,4-dimethoxyphenyl	methyl	methyl
	e	2,4-dimethoxyphenyl	methylsulfonyl	methylsulfonyl
	f	2,4-dimethoxyphenyl	2-thiophenecarbonyl	2-thiophenecarbonyl
	g	2,4-dimethoxyphenyl	H	$\alpha$ -hydroxyacetyl
	h	H	H	nicotinoyl
	i	4-methoxyphenyl	acetyl	acetyl
	j	4-methoxyphenyl	H	trifluoroacetyl
	k	4-methoxyphenyl	trifluoroacetyl	benzyl
	l	4-hydroxyphenyl	trifluoroacetyl	benzyl
	m	3,4,5-trimethoxyphenyl	H	acetyl
	n	4-methylphenyl	H	acetyl
	o	1-ethylpyrazole-5-yl	H	trifluoroacetyl
	p	4-methoxyphenyl	H	acetyl
	q	4-isobutylphenyl	H	trifluoroacetyl
	r	4-isopropylphenyl	H	trifluoroacetyl
	s	methyl	H	trifluoroacetyl

	t	benzyl	H	trifluoroacetyl
	u	2,4-dimethoxyphenyl	methyl	trifluoroacetyl

Detailed synthesis:

Synthesis of compounds **1a-j**. To a well stirred solution of 1,3-bis(t-butylthio)-acetone (10mmol),  $R^1NH_2$  (10mmol) and triethylamine  $Et_3N$ (20mmol) in dry THF(100ml), a solution of 5  $TiCl_4$ (5.5mmol) in 15ml dry hexanes was added dropwise in 30min at 0-5°C under  $N_2$ . After the addition, the reaction mixture was refluxed for 2 hours. Imine compounds so obtained were used for the next step without purification of compound **1**.

Synthesis of compounds **2a-j**. At -10°C, oxalyl chloride (0.84ml, 10mmol) was added to the 10 solution obtained in the previous step. At the same temperature and under stirring,  $Et_3N$ (20mmol) in 100ml THF was added dropwise in 30min. Then the solution was stirred at room temperature for 10 hours. The precipitate was filtered and washed with ether (250ml). The organic solution was washed with water three times and the solvent was evaporated to give a dark brown power. It was recrystallized in ethyl acetate and hexanes to give a light yellow crystal of compound **2**. All the 15 compounds **2a-j** can be prepared in the same way as described in these two steps. The total yield of these two steps for each of the compounds was about 60-70%.

Synthesis of compounds **3a-k**. A 250ml three neck flask with 50g ammonium acetate was 20 heated in oil bath under  $N_2$  till  $NH_4^+OAc^-$  melted. Compound **2**(5mmol) was added into the flask and the resulting solution was stirred for one hour. The reaction temperature was within 140°C to 165°C depending on the proprieties of compound **2**. One hour later, the heating was stopped and the 25 reaction mixture was cooled to room temperature. The reaction mixture was dissolved in 100ml water and extracted with 100ml ether three times. The extracts were combined, dried over  $Na_2SO_4$  and evaporated under reduced pressure. The residue was chromatographed on a column of silica gel to give compound **3**. Yields for **3a-i** were about 50-60%. Compound **3k** was obtained as a by product in the preparations of compound **3a-j** and it's yields depended on the reaction temperature and length of reaction time.

Synthesis of compounds **3l** and **3m**. A 150ml flask with benzylamine acetate 30g and Compound **2g** (2mmol) was heated to 170 °C under  $N_2$ . The mixture was stirred at this temperature for about one hour. When it was cooled, 50ml water was added and it was extracted with 50ml ether twice. The organic solvent was dried over  $Na_2SO_4$  and evaporated under reduced pressure. 30 The residue was purified with silica gel. Two compounds **3l** and **3m** were obtained with yields 25% and 15% respectively.

Synthesis of compounds **3n**. A 100ml flask with methylamine acetate 20g and compound **2a** (1mmol) was heated to 170 °C under  $N_2$ . The mixture was stirred at this temperature for about

one hour. When it was cooled, 50ml water was added and it was extracted with 50ml ether twice. The organic solvent was dried over  $\text{Na}_2\text{SO}_4$  and evaporated under reduced pressure. The residue was purified with silica gel. **3n** was obtained with yields of 40%.

5      **Synthesis of 4a.** To a well-stirred solution of 200mg(0.474mmol) of **3a** in 10ml of acetic anhydride, 20mg of concentrated  $\text{H}_2\text{SO}_4$  was added. Half a hour later, the solution was transferred on to a column of silica gel and developed with 200ml  $\text{CH}_2\text{Cl}_2$  then 500ml of 20% ether in  $\text{CH}_2\text{Cl}_2$  to give **4a** 190mg (0.41mmol, 86%).

10     **Synthesis of 4b.** A solution of **3a** 100mg(0.24mmol), nicotinoyl chloride hydrochloride 200mg(1.12mmol), and triethylamine 250mg (2.47mmol), in 10ml THF was stirred for 24 hours at room temperature. Afterwards 50ml of ether was added and the solution was washed with water three times. After it was dried over  $\text{Na}_2\text{SO}_4$ , the solvent was evaporated and the residue was purified on a column of silica gel to give **4b** 90mg (0.171mmol, 72%).

15     **Synthesis of 4c.** To a solution of **3a** 100mg(0.24mmol) in 5ml of dichloromethane, 300mg of trifluoroacetic anhydride was added. The resulting solution was stirred for half an hour and then the solvent was evaporated under reduced pressure to give **4c** 122mg(0.237mmol, 100%).

20     **Synthesis of 4d.** In 5ml of acetonitrile 211mg **3a**(0.5mmol), 1ml of formalin was mixed with 100mg  $\text{NaCNBH}_3$ . While stirring, 0.1ml glacial acetic acid was added dropwise over 30 minutes. This reaction mixture was stirred for 4 hours and another 0.1ml glacial acetic acid was added in the middle of the course. It was diluted with 50ml of ether and extracted with 1N  $\text{NaOH}$ , as well as with water. After it was dried and evaporated in a vacuum, the residue was chromatographed on a column of silica gel, 150mg(0.33mmol) of **4d** was obtained in 67% yield.

25     **Synthesis of 4e.** To a solution of **3a** 100mg(0.24mmol) and methylsulfonyl chloride 300mg in 5ml of dry THF, 300mg of triethylamine was added drop by drop at room temperature in one minute. This solution was stirred for half an hour and 50ml of ether was added and the solution was washed with water three times. After it was dried over  $\text{Na}_2\text{SO}_4$ , the solvent was evaporated and the residue was chromatographed on a column of silica gel to give **4e** 110mg(0.19mmol, 80%).

30     **Synthesis of 4f.** A solution of **3a** 100mg(0.24mmol), 2-thiophenecarbonyl chloride 200mg(1.37mmol) and trimethylamine 200mg(1.98mmol) in 10ml of THF was refluxed for 10 hours. Afterwards 50ml of ether was added and the solution was washed with water three times. After it was dried over  $\text{Na}_2\text{SO}_4$ , the solvent was evaporated and the residue was chromatographed on a column of silica gel to give **4f** 120mg (0.187 mmol, 79%).

35     **Synthesis of 4g.** A solution of **3a** 100mg(0.24mmol), acetoxyacetyl chloride 118mg(1.0mmol) and triethylamine 120mg(1.19mmol), in 10ml THF was stirred for 24 hours at room temperature. Afterwards 50ml of ether was added and the solution was washed with water three times. The solvent was evaporated and the residue was dissolved in a solution of 0.1N

sodium hydroxide 1ml in methanol 10ml. This solution was stirred for 1 hour. After the solvent was evaporated under reduced pressure, the residue was chromatographed on a column of silica gel to give **4g** 105mg(0.22mmol, 91%).

5      **Synthesis of 4h.** A solution of **3j** 100mg(0.35mmol), nicotinoyl chloride hydrochloride 250mg(1.40mmol), and triethylamine 350mg(3.46mmol), in 10ml THF was stirred for 24 hours at room temperature. Afterwards 50ml of ether was added and the solution was washed with water three times. After it was dried over  $\text{Na}_2\text{SO}_4$ , the solvent was evaporated and the residue was chromatographed on a column of silica gel to give **4h** 100mg(0.256mmol, 73%).

10     **Synthesis of 4i.** A solution of **3g** 100mg(0.255mmol), acetyl chloride 100mg (1.28mmol) and triethylamine 260mg(2.56mmol), in 10ml THF was stirred at 50 °C for 12 hours. Afterwards 50ml of ether was added and the solution was washed with water three times. After it was dried over  $\text{Na}_2\text{SO}_4$ , the solvent was evaporated and the residue was chromatographed on a column of silica gel to give **4i** 110mg (0.231mmol, 90%).

15     **Synthesis of 4j.** To a solution of **3g** 100mg(0.255mmol) in 5ml of dichloromethane, 300mg of trifluoroacetic anhydride was added. The solution was stirred for half a hour and then the solvent was evaporated under reduced pressure to give **4j** 125mg (0.255mmol, 100%).

20     **Synthesis of 4k.** To a solution of **3l** 50mg(0.104mmol) in 5ml of dichloromethane, 150mg of trifluoroacetic anhydride was added. The solution was stirred for half an hour and then the solvent was evaporated under reduced pressure to give **4k** 60mg (0.104mmol, 100%).

25     **Synthesis of 4l.** To a solution of **3m** 50mg(0.107mmol) in 5ml of dichloromethane, 200mg of trifluoroacetic anhydride was added. The solution was stirred for half an hour and then the solvent was evaporated under reduced pressure to give **4l** 60mg (0.107mmol, 100%).

30     **Synthesis of 4m.** A solution of **3c** 100mg(0.22mmol), acetyl chloride 70mg (0.9mmol) and triethylamine 100mg(0.99mmol), in 10ml THF was stirred at room temperature for 24 hours. Afterwards 50ml of ether was added and the solution was washed with water three times. After it was dried over  $\text{Na}_2\text{SO}_4$ , the solvent was evaporated and the residue was chromatographed on a column of silica gel to give **4m** 80mg (0.162mmol, 73%).

35     **Synthesis of 4n.** A solution of **3f** 100mg(0.266mmol), acetyl chloride 70mg (0.9mmol) and triethylamine 100mg(0.99mmol), in 10ml THF was stirred at room temperature for 24 hours. Afterwards 50ml of ether was added and the solution was washed with water three times. After it was dried over  $\text{Na}_2\text{SO}_4$ , the solvent was evaporated and the residue was chromatographed on a column of silica gel to give **4n** 90mg (0.215mmol, 81%).

40     **Synthesis of 4o.** To a solution of **3b** 80mg(0.210mmol) in 5ml of dichloromethane, 300mg of trifluoroacetic anhydride was added. The solution was stirred for half a hour and then the solvent was evaporated under reduced pressure to give **4o**, 100mg (0.210mmol, 100%).

Synthesis of 4p. A solution of 3g 100mg(0.255mmol), acetyl chloride 50mg (0.64mmol) and triethylamine 1300mg(1.28mmol), in 10ml THF was stirred at 25 °C for 24 hours. Afterwards 50ml of ether was added and the solution was washed with water three times. After it was dried over Na<sub>2</sub>SO<sub>4</sub>, the solvent was evaporated and the residue was chromatographed on a column of 5 silica gel to give 4p 90mg (0.19mmol, 70%).

Synthesis of 4q. To a solution of 3h 100mg(0.24mmol) in 5ml of dichloromethane, 300mg of trifluoroacetic anhydride was added. The solution was stirred for half a hour and then the solvent was evaporated under reduced pressure to give 4q 120mg (0.24mmol, 100%).

Synthesis of 4r. To a solution of 3i 50mg(0.124mmol) in 5ml of dichloromethane, 200mg of trifluoroacetic anhydride was added. The solution was stirred for half an hour and then the solvent was evaporated under reduced pressure to give 4r 57mg (0.124mmol, 100%).

Synthesis of 4s. To a solution of 3j 50mg in 5ml of dichloromethane, 200mg of trifluoroacetic anhydride was added. The solution was stirred for half an hour and then the solvent was evaporated under reduced pressure to give 4s 66mg. Yield: 100%.

Synthesis of 4t. To a solution of 3d 50mg in 5ml of dichloromethane, 200mg of trifluoroacetic anhydride was added. The solution was stirred for half an hour and then the solvent was evaporated under reduced pressure to give 4s 65mg. Yield: 100%.









Synthesis of 4u. To a solution of 3n 50mg in 5ml of dichloromethane, 200mg of trifluoroacetic anhydride was added. The solution was stirred for half an hour and then the solvent was evaporated under reduced pressure to give 4s 62mg Yield: 100%.

Using these intermediates the compounds of the Table 3 are prepared.

Table 3. Novel dithiolopyrrolone derivatives.

Code	X	Y	Z
BLI-017	4-Methoxyphenyl	H	Methyl
BLI-020	4-Methoxyphenyl	Acetyl	Methyl
BLI-023	4-Methoxyphenyl	H	Trifluoromethyl
BLI-031-2	2,4-Dimethoxy-phenyl	H	CH <sub>2</sub> CH <sub>2</sub> COOH
BLI-038	4-Methylphenyl	H	Methyl
BLI-044	4-Methoxyphenyl	Benzyl	Trifluoromethyl
BLI-045	4-Hydroxyphenyl	Benzyl	Trifluoromethyl
BLI-053	2,4-Dimethoxy-phenyl	H	Methyl
BLI-063	3,4,5-trimethoxy-phenyl	H	Methyl
BLI-065	2,4-Dimethoxy-phenyl	H	3-pyridyl
BLI-066	2,4-Dimethoxy-phenyl	H	N-methyl-3-pyridinium chloride
BLI-075	2,4-Dimethoxy-phenyl	H	Trifluoromethyl

BLI-079	1-ethylpyrazole-5-yl	H	Trifluoromethyl
BLI-081	2,4-Dimethoxy-phenyl	H	2-furyl
BLI-090	2,4-Dimethoxy-phenyl	H	2,4-dimethoxyphenyl
BLI-093	2,4-Dimethoxy-phenyl	H	4-Trifluoromethylphenyl
WBL-004	2,4-Dimethoxy-phenyl	2-thio-phenylcarboxy	2-thiophenyl
WBL-007	2,4-Dimethoxy-phenyl	H	2-thiophenyl
R1	2,4-Dimethoxy-phenyl	H	Hydroxymethyl
R2	2,4-Dimethoxy-phenyl	H	hexyl
R3	2,4-Dimethoxy-phenyl	H	3, 5-difluorophenyl
R4	2,4-Dimethoxy-phenyl	H	2,3,4-trifluorophenyl
WBL-018	2,4-Dimethoxy-phenyl	H	4-fluoro-phenyl
0037	2,4-Dimethoxy-phenyl	H	Thiophene-2-methyl
0038	2,4-Dimethoxy-phenyl	H	4-nitrophenyl
0039	2,4-Dihydroxyphenyl	H	methyl
0040	2,4-Dimethoxy-phenyl	H	4-N,N-dimethylamine-phenyl
0041	2,4-Dimethoxy-phenyl	H	4-aminophenyl
0042	2,4-Dimethoxy-phenyl	H	
0043	2,4-Dimethoxy-phenyl	H	
0044	2,4-Dimethoxy-phenyl	H	
0047	2,4-Dimethoxy-phenyl	H	3-trifluoromethylphenyl
0052	2,4-Dimethoxy-phenyl	H	
JS-26	2,4-Dimethoxy-phenyl	H	
0054	4-iso-butylphenyl	H	4-trifluoromethylphenyl
0055	4-iso-butylphenyl	H	2-furyl
0056	4-iso-butylphenyl	H	2-thiophenyl
0057	4-iso-butylphenyl	H	3-trifluoromethylphenyl
0058	2,4-Dimethoxy-phenyl	H	3,5-di-trifluoromethylphenyl
0059	4-iso-butylphenyl	H	3,5-di-trifluoromethylphenyl
0062	2,4-Dimethoxy-phenyl	H	

0066	2,4-Dimethoxy-phenyl	H	
0068	2,4-Dimethoxy-phenyl	H	
0069	2,4-Dimethoxy-phenyl	H	
WBI-4	4-isopropylphenyl	H	
WBI-5	4-isobutylphenyl	H	
WBI-6	methyl	H	
0096	4-isopropanylphenyl	H	3,5-dihydroxy-4-isopropyl-phenyl
0102	2,4-Dimethoxy-phenyl	H	3,5-dihydroxy-4-isopropyl-phenyl
0107	Benzyl	H	3,5-dihydroxy-4-isopropyl-phenyl
0110	methyl	H	3,5-dihydroxy-4-isopropyl-phenyl
0113	Benzyl	H	2-thiophenyl
0116	Benzyl	H	
0122	2,4-Dimethoxy-phenyl	methyl	
0125	4-isopropanylphenyl	H	
0126	2,4-Dimethoxy-phenyl	H	
0128	4-isopropanylphenyl	H	Pyridine-3-yl
0135	Benzyl	H	Pyridine-3-yl
0136	Benzyl	H	
0137	Benzyl	H	
CSL-25	Phenyl	H	Methyl
CSL-26	Benzyl	H	Phenyl
CSL-28	H	H	3-pyridyl
	2,4-Dimethoxy-phenyl	H	2-(2-thiophenyl)-vinyl
	2,4-Dimethoxy-phenyl	H	1-methylimidazol-5-yl
	4-Methyl-phenyl	H	2-thiophenyl
	H	H	2-thiophenyl
	H	Methyl	2-thiophenyl
	2,4-Dimethoxy-phenyl	Methyl	2-thiophenyl
	2,4-Dimethoxy-phenyl	benzyl	2-furyl

	2,4-Dimethoxy-phenyl	H	1-methyl- pyrrolyl
	cyclohexyl	H	phenyl
	benzyl	H	phenyl
	H	cyclohexyl	phenyl
	H	2-thiazolyl	phenyl
	2,4-dimethoxy-phenyl	H	2-thiazolyl
	2,4-Dimethoxy-phenyl	H	propyl
	2,4-Dimethoxy-phenyl	H	N-methy-2-lindolyl

Synthesis of **BLI-017**. A solution of **4p** 90mg(0.19mmol) and  $\text{Hg}(\text{OAc})_2$  6.8mg (0.19mmol) in 10ml TFA was stirred at room temperature for one hour. After TFA was evaporated under reduced pressure, the residue was dissolved in 100ml  $\text{CH}_3\text{CN}$ .  $\text{H}_2\text{S}$  was bubbled into the solution.

5 One hour later,  $\text{N}_2$  was bubbled into the solution to drive away trace of  $\text{H}_2\text{S}$ , then 0.20mmol  $\text{I}_2$  in 10 ml  $\text{CH}_2\text{Cl}_2$  was added to the solution. Half an hour later, the solvent was evaporated under reduced pressure and the residue was chromatographed in a column of silica gel to give **BLI-017** 43mg. Yield 67%.  $^1\text{H}$  NMR(100 MHz,  $\text{CDCl}_3$ )  $\delta$  2.2(s, 3H), 3.9(s, 3H), 6.7(s, 1H), 7.0-7.4(dd, 4H), 7.8(s, 1H).

10 Synthesis of **BLI-020**. **BLI-020** was synthesized from **4i** by the same method of synthesis as **BLI-017**. Yield 60%.  $^1\text{H}$  NMR(100 MHz,  $\text{CDCl}_3$ )  $\delta$  2.5(s, 6H), 3.9(s, 3H), 6.95(s, 1H), 7.0-7.5(dd, 4H), MS(CI): 363(M+1).

15 Synthesis of **BLI-023**. **BLI-023** was synthesized from **4j** by the same method of synthesis as **BLI-017**. Yield 75%.  $^1\text{H}$  NMR(100 MHz,  $\text{CDCl}_3$ )  $\delta$  3.9(s, 3H), 6.82(s, 1H), 7.0-7.4(dd, 4H), 8.3(s, 1H).

Synthesis of **BLI-038**. **BLI-038** was synthesized from **4n** by the same method of synthesis as **BLI-017**. Yield: 70%.  $^1\text{H}$  NMR(100 MHz,  $\text{CDCl}_3$ )  $\delta$  2.1(s, 3H), 2.4(s, 3H), 6.7(s, 1H), 7.3(s, 4H), 8.0(s, 1H).

20 Synthesis of **BLI-044**. **BLI-044** was synthesized from **4k** by the same method of synthesis as **BLI-017**. Yield: 72%.  $^1\text{H}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  3.9(s, 3H), 4.2-5.8(dd, 2H), 6.9(s, 1H), 7.0-7.4(dd, 4H), 7.4(s, 5H). MS(CI): 465(M+1).

Synthesis of **BLI-045**. **BLI-045** was synthesized from **4l** by the same method of synthesis as **BLI-017**. Yield: 65%.  $^1\text{H}$  NMR(100 MHz,  $\text{CDCl}_3$ )  $\delta$  4.2-5.8(dd, 2H), 6.6(s, 1H), 7.1-7.5(broad peak, 9H), 7.4(s, 5H).

25 Synthesis of **BLI-053**. **BLI-053** was synthesized from **4** by the same method of synthesis as **BLI-017**. Yield: 77%.  $^1\text{H}$  NMR(100 MHz,  $\text{CDCl}_3$ )  $\delta$  3.77(s, 3H), 3.82(s, 3H), 6.6(s, 1H), 6.4-7.3(multi, 3H), 8.0(broad peak, 1H). MS: 350(M).

Synthesis of **BLI-063**. **BLI-063** was synthesized from **4m** by the same method of synthesis as **BLI-017**. Yield: 55%.  $^1\text{H}$  NMR(100 MHz,  $\text{CDCl}_3$ )  $\delta$  3.8(s, 6H), 3.9(s, 3H), 6.7(s, 1H), 7.4(s, 2H), 7.9(broad peak, 1H). MS: 380(M).

Synthesis of **BLI-065**. **BLI-065** was synthesized from **4b** by the same method of synthesis as **BLI-017**. Yield: 45%.  $^1\text{H}$  NMR(100 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  3.8(s, 3H), 3.9(s, 3H), 6.7(s, 1H), 6.6-9.2(multi, 7H).

Synthesis of **BLI-066**. 10mg(0.024mmol) **BLI-065** was dissolved in 1ml  $\text{CH}_3\text{I}$  and the solution left at room temperature for 10 hours. Red crystals formed in the solution which was filtered and 9mg(0.016mmol) **BLI-066** was obtained in 67%.  $^1\text{H}$  NMR(100 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  3.7(s, 3H), 3.8(s, 3H), 4.4(s, 3H), 6.9(s, 1H), 6.5-9.4(multi, 7H).

Synthesis of **BLI-075**. **BLI-075** was synthesized from **4c** by the same method of synthesis as **BLI-017**. Yield: 83%.  $^1\text{H}$  NMR(100 MHz,  $\text{CDCl}_3$ )  $\delta$  3.8(s, 3H), 3.9(s, 3H), 6.6(multi, 3H), 7.2(d, 1H), 8.4(s, 1H). MS: CI 405(M+1).

Synthesis of **BLI-079**. **BLI-079** was synthesized from **4o** by the same method of synthesis as **BLI-017**. Yield: 6.6%.  $^1\text{H}$  NMR(100 MHz,  $\text{CDCl}_3$ )  $\delta$  1.5(t, 3H), 4.0(q, 2H), 6.3(d, 1H), 6.9(s, 1H), 7.7(d, 1H), 8.4(s, 1H). MS: CI 363(M+1).

Synthesis of **0024**. **0024** was synthesized from **4d** by the same method of synthesis as **BLI-017**. Yield: 19%.  $^1\text{H}$  NMR(100 MHz,  $\text{CDCl}_3$ )  $\delta$  2.6(s, 6H), 3.8(s, 3H), 3.9(s, 3H), 6.4(s, 1H), 6.5(multi, 2H), 7.2(d, 1H). MS: 337(M+1).

Synthesis of **WBL-004**. **WBL-004** was synthesized from **4f** by the same method of synthesis as **BLI-017**. Yield: 43%.  $^1\text{H}$  NMR (100 MHz,  $\text{CDCl}_3$ ),  $\delta$  3.8(s, 3H), 3.9(s, 3H), 6.5(s, 1H), 6.65(multi, 4H), 7.2(multi, 2H), 7.7(multi, 3H). MS: 529(M+1).

Synthesis of **R1**. **R1** was synthesized from **4g** by the same method of synthesis as **BLI-017**. Yield: 41%.  $^1\text{H}$  NMR (100 MHz,  $\text{CDCl}_3$ ),  $\delta$  3.8(s, 3H), 3.9(s, 3H), 4.3(s, 2H), 6.5(s, 1H), 6.65(multi, 2H), 7.2(d, 1H), 8.35(s, 1H). MS: 367(M+1).

Synthesis of **CSL-25**. **CSL-25** was synthesized using the procedure of Scheme 1. **CSL-25** has the following characteristics:  $^1\text{H}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  2.2(s, 3H), 6.8(s, 1H), 7.4-7.6(multi, 5H), 7.8(s, 1H).

Synthesis of **CSL-26**. **CSL-26** was synthesized using the procedure of Scheme 1. **CSL-26** has the following characteristics:  $^1\text{H}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  5.1(s, 2H), 6.5(s, 1H), 7.2-8.0(multi, 10H), 8.3(s, 1H).

Synthesis of **CSL-28**. **CSL-28** was synthesized from **4h** by the same method of synthesis as **BLI-017**. Yield: 43%.  $^1\text{H}$  NMR (100 MHz,  $\text{CDCl}_3$ ),  $\delta$  6.8(s, 1H), 7.9(s, 1H), 8.1-9.2(multi 4H), MS: CI, 278(M+1).

Synthesis of **0050**. **0050** was synthesized from **4q** by the same method of synthesis as **BLI-017**. Yield: 80%.  $^1\text{H}$  NMR (100 MHz,  $\text{CDCl}_3$ ),  $\delta$  0.9(t, 3H), 1.3(d, 3H), 1.65(multi, 2H), 2.7(multi, 1H), 6.9(s, 1H), 7.3(s, 4H), 8.4(s, 1H).

5 Synthesis of **0061**. **0061** was synthesized from **4s** by the same method of synthesis as **BLI-017**. Yield: 82%.  $^1\text{H}$  NMR (100 MHz,  $\text{CDCl}_3$ ), 2.8(s, 3H), 6.6(s, 1H), 8.4(s, 1H).


Synthesis of **0092**. **0092** was synthesized from **4r** by the same method of synthesis as **BLI-017**. Yield: 77%.  $^1\text{H}$  NMR (100 MHz,  $\text{CDCl}_3$ ),  $\delta$  1.26(d, 6H), 3.0(multi, 1H), 6.7(s, 1H), 7.35(s, 4H), 8.6(s, 1H).

10 Synthesis of **0103**. **0103** was synthesized from **4t** by the same method of synthesis as **BLI-017**. Yield: 85%.  $^1\text{H}$  NMR (100 MHz,  $\text{CDCl}_3$ ), 4.3(s, 2H), 6.6(s, 1H), 7.3(s, 5H), 8.4(s, 1H).

Synthesis of **0119**. **0119** was synthesized from **4u** by the same method of synthesis as **BLI-017**. Yield: 85%.  $^1\text{H}$  NMR (100 MHz,  $\text{CDCl}_3$ ),  $\delta$  2.7(s, 3H), 3.8(s, 3H), 3.85(s, 3H), 6.55(s, 1H), 6.6(multi, 2H), 7.2(d, 1H), 8.4(s, 1H).

## 15 EXAMPLE 4

The following compounds of the Examples 1-3 are prepared according to the following synthetic scheme (Scheme 2):



Scheme 2

According to this scheme the following intermediates are synthesized

Code	X	Y
0021	2,4-dimethoxyphenyl	H
0051	4-isobutylphenyl	H
0079	Methyl	H
0093	4-isopropylphenyl	H
0104	Benzyl	H
0120	2,4-dimethoxyphenyl	Methyl

Detailed synthesis:

Synthesis of **0021**. 1g **BLI-075** was dissolved in a solution of 5ml hydrochloric acid in 5 150ml methanol. The solution was refluxed for 2 hours. After the solvent was evaporated in vacuum, 0.76g **0021** was collected as a dark green powder.

Synthesis of **BLI-081**. 50mg(0.16mmol) **0021** was dissolved in 20ml dry THF. While thoroughly stirring, 43mg(0.32mmol) 2-furoyl chloride was added first then 50mg triethylamine was added dropwise over 2 minutes. The reaction was completed in half an hour and the product 10 was purified by a column of silica gel to give 51mg(0.12 mmol, 80%) **BLI-081**. <sup>1</sup>H NMR(100 MHz, CDCl<sub>3</sub>) δ3.8(s, 3H), 3.9(s, 3H), 6.5(s, 1H), 6.6(s, multi, 3H), 7.2(multi, 2H), 7.6(d, 1H), 8.4(s, 1H). MS: 403(M+1).

Synthesis of **BLI-090**. **BLI-090** was synthesized by the reaction of **0021** with 2,4-dimethoxy benzoyl chloride by the same method of synthesis as **BLI-081**. Yield: 89%. <sup>1</sup>H NMR(100 MHz, CDCl<sub>3</sub>) δ3.8(s, 3H), 3.9(s, 3H), 3.93(s, 3H), 4.07(s, 3H), 6.4(s, 1H), 6.6(multi, 4H), 7.2(d, 1H), 8.2(d, 1H), 10.2(s, 1H). MS: 473(M+1).

Synthesis of **BLI-093**. **BLI-093** was synthesized by the reaction of **0021** with 4-trifluoromethyl benzoyl chloride by the same method of synthesis as **BLI-081**. Yield: 90%. <sup>1</sup>H NMR(100 MHz, CDCl<sub>3</sub>) δ3.8(s, 3H), 3.9(s, 3H), 6.5(s, 1H), 6.6(multi, 2H), 7.25(d, 1H), 7.8(d, 2H), 20 8.1(d, 2H), 8.4(s, 1H). MS: 480(M).

Synthesis of **WBL-007**. **WBL-007** was synthesized by the reaction of **0021** with 2-thiophenecarbonyl chloride by the same method of synthesis as **BLI-081**. Yield: 88%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ3.8(s, 3H), 3.9(s, 3H), 6.55(s, 1H), 6.63(multi, 2H), 7.2(multi, 2H), 7.7(multi, 2H). MS: 418(M).

Synthesis of **R2**. **R2** was synthesized by the reaction of **0021** with heptanoyl chloride by the 25 same method of synthesis as **BLI-081**. Yield: 74%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ0.9 (t, 3H), 1.4(multi, 8H), 2.4(t, 2H), 3.8(s, 3H), 3.9(s, 3H), 4.3(s, 2H), 6.6(s, 1H), 6.65(multi, 2H), 7.2(d, 1H), 8.4(s, 1H). MS: 420(M).

Synthesis of R3. R3 was synthesized by the reaction of 0021 with 3,4-difluorobenzoyl chloride by the same method of synthesis as **BLI-081**. Yield: 81%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ3.8(s, 3H), 3.9(s, 3H), 6.5(s, 1H), 6.6 (multi, 2H), 7.1 (multi, 2H), 7.5(multi, 2H), 8.4(s, 1H). MS: 448(M).

5      Synthesis of R4. R4 was synthesized by the reaction of 0021 with 2,3,4-trifluorobenzoyl chloride by the same method of synthesis as **BLI-081**. Yield: 84%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ3.8(s, 3H), 3.9(s, 3H), 6.5(s, 1H), 6.6 (multi, 2H), 7.2 (multi, 2H), 7.9(multi, 1H), 8.6(s, 1H). MS: 466(M).

10     Synthesis of WBL-018. WBL-018 was synthesized by the reaction of 0021 with 4-fluorobenzoyl chloride by the same method of synthesis as **BLI-081**. Yield: 85%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ3.8(s, 3H), 3.9(s, 3H), 6.5(s, 1H), 6.65(multi, 3H), 7.1 (multi, 2H), 7.5(multi, 2H), 8.4(s, 1H). MS: 430(M).

15     Synthesis of 0037. 0037 was synthesized by the reaction of 0021 with thiopheneacetyl chloride by the same method of synthesis as **BLI-081**. Yield: 81%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ3.75(s, 3H), 3.85(s, 3H), 3.9(s, 2H), 6.42(s, 1H), 6.55(multi, 2H), 7.1-7.3 (multi, 4H), 8.2(s, 1H).

20     Synthesis of 0038. 0038 was synthesized by the reaction of 0021 with 4-nitrobenzoyl chloride by the same method of synthesis as **BLI-081**. Yield: 81%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ3.8(s, 3H), 3.85(s, 3H), 6.55(multi, 3H), 7.1-7.3 (dd, 1H), 8.2(dd, 4H), 8.9(s, 1H).

25     Synthesis of 0040. 100mg(0.32mmol), 0021 55mg(0.32mmol) 4-(dimethylamino)benzoic acid and 75mg(0.34mmol)DCC were dissolved in 20ml dry CH<sub>2</sub>Cl<sub>2</sub>. This solution had been stirred for 2 hours. After the solvent was evaporated, product was purified by a column of silica gel to give 65mg(60%) 0040. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ3.1(s, 6H), 3.8(s, 3H), 3.85(s, 3H), 6.4(s, 1H), 6.5(multi, 2H), 6.8(d, 2H), 7.25(d, 1H), 7.85(d, 2H), 8.1(s, 1H).

30     Synthesis of 0041. 100mg(0.32mmol), 0021 80mg(0.32mmol) 4-trifluoroacetamidobenzoic acid and 75mg(0.34mmol) DCC were dissolved in 20ml dry CH<sub>2</sub>Cl<sub>2</sub>. This solution had been stirred for 2 hours. After the solvent was evaporated, residue was dissolved in 40ml methanol. To this solution 2ml concentrated HCl was added and the resulting solution was refluxed for 1 hour. Product was extracted with ethyl acetate and washed with water dried on sodium sulfate. After solvent was evaporated the residue was chromatographed on a column of silica gel to give 50mg(40%) 0041. <sup>1</sup>H NMR (100 MHz, DMSO-d<sub>6</sub>), δ3.7(s, 3H), 3.8(s, 3H), 5.9(s, 2H), 6.6(d, 2H), 6.7 (multi, 2H), 6.8(s, 1H), 7.2(d, 1H), 7.75(d, 2H), 9.55(s, 1H).

35     Synthesis of 0042. 100mg(0.32mmol), 0021, 100mg(0.33mmol) 2,3:4,6-di-O-isopropylidene-2-keto-L-gulonic acid monohydrate and 80mg(0.35mmol) DCC were dissolved in 20ml dry CH<sub>2</sub>Cl<sub>2</sub>. This solution had been stirred for 2 hours. After the solvent was evaporated, residue was chromatographed on a column of silica gel to give 110mg(60%) 0042. <sup>1</sup>H NMR (100

MHz, CDCl<sub>3</sub>), δ1.4(s, 3H), 1.42(s, 3H), 1.6(s, 6H), 3.75(s, 3H), 3.85(s, 3H), 4.1-4.7(multi, 5H), 6.4(s, 1H), 6.5-6.6(multi, 2H), 7.2(d, 1H), 9.0(s, 1H).

5      **Synthesis of 0043.** A solution of 50mg **0042** in 20ml mixture of 1N HCl and THF(1:5) was stirred at room temperature for 3 hours. Product was extracted with ethyl acetate and washed with water. After solvent was evaporated, residue was chromatographed on a column of silica gel to give 42mg(85%) **0043**. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ1.4(s, 3H), 1.42(s, 3H), 3.8(s, 3H), 3.9(s, 3H), 4.1-4.7(multi, 5H), 6.5(s, 1H), 6.5-6.6(multi, 2H), 7.2(d, 1H), 9.0(s, 1H).

10     **Synthesis of 0044.** A solution of 50mg **0042** in 20ml mixture of acetic acid and water(7:3) was refluxed for 4 hours. Solvents were evaporated under reduced pressure. Residue was chromatographed on a column of silica gel to give 36mg(85%) **0044**. <sup>1</sup>H NMR(100 MHz, CDCl<sub>3</sub>), δ2.6-4.5(broad, 10H), 3.8(s, 3H), 3.9(s, 3H), 6.5-6.6(multi, 3H), 7.2(d, 1H), 9.0(s, 1H).

15     **Synthesis of 0047.** The synthesis of **0047** was achieved by the reaction of **0021** with 3-trifluoromethylbenzoyl chloride by the same method of synthesis as **BLI-081**. Yield: 85%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ3.8(s, 3H), 3.85(s, 3H), 6.55(s, 1H), 6.6(multi, 2H), 7.2(d, 1H), 7.8(s, 1H), 7.7-8.4(multi, 4H).

20     **Synthesis of 0051.** The synthesis of **0051** was achieved form **0050** by the same method of synthesis as **0021**. Yield: 90%.

25     **Synthesis of 0052.** 100mg **0021** was dissolved in 40ml dry THF. While stirring thoroughly, 100mg chloroacetyl chloride was added then 50mg triethylamine was added dropwise over 2 minutes. The reaction was completed in half an hour. Product was extracted with ethyl acetate and washed with water. After the solvent was evaporated the residue was dissolved in 10ml of acetonitrile. To this solution, 0.5ml of morpholine was added and the solution was stirred at 60°C for 4 hours. Product was extracted with ethyl acetate and washed with water. After solvent was evaporated, residue was chromatographed on a column of silica gel to give **0052** 65mg Yield: 50%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ2.8(multi, 4H), 3.8(multi, 4H), 3.81(s, 3H), 3.85(s< 3H), 6.45(s, 1H), 6.6(multi, 2H), 7.25(d, 1H), 9.45(s, 1H).

30     **Synthesis of 0054.** The compound **0054** was synthesized by the reaction of **0051** and 4-trifluoromethyl benzoyl chloride using the same method of synthesis as for **BLI-081**. Yield: 85%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ0.9(t, 3H), 1.3(d, 3H), 1.65(multi, 2H), 2.7(multi, 1H), 6.9(s, 1H), 7.3(s, 4H), 7.8(d, 2H), 8.1(d, 2H), 8.4(s, 1H).

35     **Synthesis of 0055.** The compound **0055** was synthesized by the reaction of **0051** and 2-furoyl chloride using the same method of synthesis as for **BLI-081**. Yield: 90%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ0.9(t, 3H), 1.3(d, 3H), 1.65(multi, 2H), 2.7(multi, 1H), 6.6(dd, 1H), 6.9(s, 1H), 7.3(s, 4H), 7.4(d, 1H), 7.6(d, 1H), 8.4(s, 1H).

Synthesis of 0056. The compound 0056 was synthesized by the reaction of 0051 and 2-thiophenecarbonyl chloride using the same method of synthesis as for BLI-081. Yield: 90%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ0.9(t, 3H), 1.3(d, 3H), 1.65(multi, 2H), 2.7(multi, 1H), 6.85(s, 1H), 7.2(dd, 1H), 7.3(s, 4H), 7.6(d, 2H), 7.8(d, 2H), 8.2(s, 1H).

5       Synthesis of 0057. The compound 0057 was synthesized by the reaction of 0051 and 3-trifluoromethyl benzoyl chloride using the same method of synthesis as for BLI-081. Yield: 88%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ0.9(t, 3H), 1.3(d, 3H), 1.65(multi, 2H), 2.7(multi, 1H), 6.9(s, 1H), 7.35(s, 4H), 7.6-8.3(multi, 4H), 8.4(s, 1H).

10      Synthesis of 0058. The compound 0058 was synthesized by the reaction of 0021 and 3,5-di-trifluoromethyl benzoyl chloride using the same method of synthesis as for BLI-081. Yield: 88%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ3.8(s, 3H), 3.85(s, 3H), 6.55(s, 1H), 6.6(multi, 2H), 7.2(d, 1H), 8.1(s, 1H), 8.4(s, 2H), 8.6(s, 1H).

15      Synthesis of 0059. The compound 0059 was synthesized by the reaction of 0051 and 3,5-di-trifluoromethyl benzoyl chloride using the same method of synthesis as for BLI-081. Yield: 80%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ0.9 (t, 3H), 1.3(d, 3H), 1.65(multi, 2H), 2.7(multi, 1H), 6.95(s, 1H), 7.3(s, 4H), 8.1(s, 1H), 8.4(s, 2H), 8.6(s, 1H).

20      Synthesis of 0062. 100mg 0021 was dissolved in 40ml dry THF. While stirring thoroughly, 100mg chloroacetyl chloride was added, then 100mg triethylamine was added dropwise over 2 minutes. The reaction was completed in half an hour. Product was extracted with ethyl acetate and washed with water. After the solvent was evaporated the residue was dissolved in 10ml of DMF. To this solution, 200mg of piperazine was added and the solution was stirred at 60°C for 4 hours. Product was extracted with ethyl acetate and washed with water. After solvent was evaporated, the residue was chromatographed on a column of silica gel to give 0062 70mg Yield: 53%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ2.7(multi, 4H), 3.1(multi, 4H), 3.2(s, 2H), 3.4(s, 1H), 3.8(s, 3H), 3.9(s, 3H), 6.4(s, 1H), 6.6(multi, 2H), 7.2(d, 1H), 9.2(s, 1H).

25      Synthesis of 0066. 100mg 0021 was dissolved in 40ml dry THF. While stirring thoroughly, 120mg 4-chloromethyl benzoic chloride was added then 100mg triethylamine was added dropwise over 2 minutes. The reaction was completed in half an hour. Product was extracted with ethyl acetate and washed with water. After the solvent was evaporated the residue was dissolved in 2ml of morpholine. This solution was stirred at 60°C for 2 hours and water was added. Product was extracted with ethyl acetate and washed with water. After solvent was evaporated, the residue was chromatographed on a column of silica gel to give 0066 110mg. Yield: 68%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ2.5 (multi, 4H), 3.8(multi, 4H), 3.6(s, 2H), 3.85(s, 3H), 3.9(s, 3H), 6.5(s, 1H), 6.6(multi, 2H), 7.2(d, 1H), 7.7(dd, 4H), 8.3(s, 1H).

Synthesis of 0068. 100mg **0021** was dissolved in 40ml dry THF. While stirring thoroughly, 120mg 4-chloromethyl benzoic chloride was added then 100mg triethylamine was added dropwise over 2 minutes. The reaction was completed in half an hour. Product was extracted with ethyl acetate and washed with water. After the solvent was evaporated the residue was dissolved in 2ml of N-methyl piperazine. This solution was stirred at 60°C for 2 hours and water was added. Product was extracted with ethyl acetate and washed with water. After solvent was evaporated, the residue was chromatographed on a column of silica gel to give **0068** 120mg Yield: 70%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ2.4(s, 3H), 2.6(s, 8H), 3.6(s, 2H), 3.85(s, 3H), 3.9(s, 3H), 6.45(s, 1H), 6.6(multi, 2H), 7.2(d, 1H), 7.7(dd, 4H), 8.3(s, 1H).

Synthesis of 0069. 100mg **0021** was dissolved in 40ml dry THF. While stirring thoroughly, 120mg 4-chloromethyl benzonyl chloride was added, then 100mg triethylamine was added dropwise over 2 minutes. The reaction was completed in half an hour. Product was extracted with ethyl acetate and washed with water. After the solvent was evaporated the residue was dissolved in 10ml of DMF. To this solution, 200mg of piperazine was added and the solution was stirred at 60°C for 4 hours. Product was extracted with ethyl acetate and washed with water. After the solvent was evaporated, the residue was chromatographed on a column of silica gel to give **0069** 125mg Yield: 70%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ2.6(s, 4H), 3.1(multi, 4H), 3.6(s, 2H), 3.85(s, 3H), 3.9(s, 3H), 6.5(s, 1H), 6.6(multi, 2H), 7.25(d, 1H), 7.7(dd, 4H), 8.4(s, 1H).

Synthesis of 0079. The compound **0079** was synthesized from **0061** by the same method as the synthesis of **0021**. It is a dark green powder.

Synthesis of 0080. 80mg **0079** was dissolved in 20ml of dry THF. To this solution 150mg of 3-nicotinoyl carbonyl chloride was added and 100mg of triethylamine was added dropwise. The resulting solution was stirred at room temperature for half an hour. Product was extracted with ethyl acetate and washed with water. After solvent was evaporated, the residue was chromatographed on a column of silica gel to give **0080** 90mg. Yield 80%. <sup>1</sup>H NMR(100 MHz, CD<sub>3</sub>OD) δ2.8(s, 3H), 6.7(s, 1H), 7.6(d, 1H), 8.4(dd, 1H), 8.7(s, 1H), 8.9(d, 1H), 9.2(s, 1H).

Synthesis of 0110. 80mg **0079** was dissolved in 20ml of dry THF. To this solution 180mg of 3,5-dimethoxyl-4-isopropyl benzoyl chloride was added and 100mg of triethylamine was added dropwise while stirring. The resulting solution was stirred at room temperature for half an hour. Product was extracted with ethyl acetate and washed with water. After the solvent was evaporated, the residue was dissolved in 5ml of dichloromethane and to this solution, 100mg BBr<sub>3</sub> was added at -78°C. This solution was stirred overnight at room temperature, then 100ml water was added and the product was extracted with ethyl acetate and dried on sodium sulfate. After solvent was evaporated, the residue was chromatographed on a column of silica gel to give **0110** 50mg. Yield

40%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ1.24 (d, 3H), 1.26(d, 3H), 3.1(multi, 1H), 2.75(s, 3H), 6.6(s, 1H), 6.95(s, 2H), 8.3(s, 1H).

Synthesis of 0093. The compound 0093 was synthesized from 0092 by the same method as the synthesis of 0021. It is a dark green powder.

5       Synthesis of 0096. 100mg 0093 was dissolved in 20ml of dry THF. To this solution 180mg of 3,5-dimethoxyl-4-isopropyl benzoyl chloride was added and 100mg of triethylamine was added dropwise while stirring. The resulting solution was stirred at room temperature for half an hour. Product was extracted with ethyl acetate and washed with water. After solvent was evaporated, the residue was dissolved in 5ml of dichloromethane and to this solution, 100mg BBr<sub>3</sub> was added at –  
10 78°C. This solution was stirred overnight at room temperature, then 100ml water was added and the product was extracted with ethyl acetate and dried on sodium sulfate. After solvent was evaporated, the residue was chromatographed on a column of silica gel to give 0096 60mg. Yield 43%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ1.24(d, 6H), 1.26(d, 6H), 3.05(multi, 2H), 6.88(s, 1H), 6.98(s, 2H), 7.3(s, 4H).

15      Synthesis of 0102. 0021 100mg, 3,5-diacetoxy-4-isopropyl benzoic acid 80mg and DCC 80mg were added in 10ml dry dichloromethane. This solution was stirred for 2 hours at room temperature. After purification by column chromatographer, the product was dissolved in 20ml methanol. To this solution, a solution of 50mg sodium carbonate in 2ml water was added and the resulting solution was stirred at 50°C for 4 hour. Product was extracted with ethyl acetate and washed with water and purified by column to give 0102 30mg. Yield: 16%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ1.24(d, 6H), 1.26(d, 6H), 3.1(multi, 1H), 3.75(s, 3H), 3.85(s, 3H), 6.6(s, 1H), 6.62(multi, 2H), 6.95(s, 2H), 7.2(d, 1H), 8.3(s, 1H).

Synthesis of 0104. The compound 0104 was synthesized from 0103 by the same method as the synthesis of 0021. It's also a dark green powder.

25      Synthesis of 0107. The compound 0107 was synthesized from 0104 by the same method as the synthesis of 0096. Yield 52%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ1.25(d, 3H), 1.27(d, 3H), 3.05(multi, 1H), 5.02(s, 2H), 6.6(s, 1H), 6.95(s, 2H), 7.1(s, 5H), 8.4(s, 1H).

30      Synthesis of 0113. The compound 0113 was synthesized by the reaction of 0104 and 2-thiophenecarbonyl chloride by the same method of synthesis as BLI-081. Yield: 90%. <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ5.05(s, 2H), 6.85(s, 1H), 7.2(dd, 1H), 7.25(s, 5H), 7.6(d, 1H), 7.8(d, 1H), 8.3(s, 1H).

Synthesis of 0116. The compound 0116 was synthesized from 0104 by the same method of synthesis as 0066. Yield: 50% <sup>1</sup>H NMR (100 MHz, CDCl<sub>3</sub>), δ2.5(multi, 4H), 3.6(s, 2H), 3.8(multi, 4H), 4.9(s, 2H), 6.5(s, 1H), 7.12(s, 5H), 7.6(dd, 4H), 8.3(s, 1H).

Synthesis of **0120**. The compound **0120** was synthesized from **0119**, as a dark green powder by the same method as the synthesis as **0021**.

Synthesis of **0122**. The compound **0122** was synthesized from **0120** by the same method of synthesis as **0066**. Yield: 55%.  $^1\text{H}$  NMR (100 MHz,  $\text{CDCl}_3$ ),  $\delta$  2.5(multi, 4H), 2.9(s, 3H), 3.6(s, 2H), 5 3.8(multi, 4H), 3.85(s, 3H), 3.9(s, 3H), 6.6(s, 1H), 6.7(multi, 2H), 7.2(d, 1H), 7.7(dd, 4H), 8.4

Synthesis of **0125**. 100mg **0093** was dissolved in 40ml dry THF. While stirring thoroughly, 120mg 3-chloromethyl benzoic chloride was added, then 100mg triethylamine was added dropwise over 2 minutes. The reaction was completed in half an hour. Product was extracted with ethyl acetate and washed with water. After the solvent was evaporated the residue was dissolved in 2ml 10 of morpholine. This solution was stirred at  $60^\circ\text{C}$  for 2 hours and water was added. Product was extracted with ethyl acetate and washed with water. After solvent was evaporated, the residue was chromatographed on a column of silica gel to give **0125** 100mg. Yield: 60%.  $^1\text{H}$  NMR (100 MHz,  $\text{CDCl}_3$ ),  $\delta$  1.27(d, 6H), 2.6(multi, 4H), 3(multi, 1H), 3.65(s, 2H), 3.8(multi, 4H), 6.85(s, 1H), 7.4(s, 4H), 7.4-8.0(multi, 4H), 8.35(s, 1H).

Synthesis of **0126**. The compound **0126** was synthesized from **0021** by the same method of synthesis as **0125**. Yield: 60%.  $^1\text{H}$  NMR (100 MHz,  $\text{CDCl}_3$ ),  $\delta$  2.55(multi, 4H), 3.6(s, 2H), 3.8(multi, 4H), 3.85(s, 3H), 3.9(s, 3H), 6.45(s, 1H), 6.6(multi, 2H), 7.25(d, 1H), 7.4-8.0(multi, 4H), 8.25(s, 1H).

Synthesis of **0128**. The compound **0128** was synthesized from **0093** by the same method of synthesis as **0080**. Yield: 80%.  $^1\text{H}$  NMR (100 MHz,  $\text{CDCl}_3$ ),  $\delta$  1.26(d, 6H), 3.0(multi, 1H), 7.02(s, 1H), 7.35(s, 4H), 7.8(s, 1H), 8.7(s, 1H), 9.0(s, 1H), 9.2(s, H), 9.4(s, 1H).

Synthesis of **0135**. The compound **0135** was synthesized from **0104** by the same method of synthesis as **0080**. Yield: 82%.  $^1\text{H}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  4.1(s, 2H), 6.7(s, 1H), 7.25(s, 5H), 7.6(d, 1H), 8.4(dd, 1H), 8.7(s, 1H), 8.9(d, 1H), 9.2(s, 1H).

Synthesis of **0136**. 100mg **0104** was dissolved in 40ml dry THF. While stirring thoroughly, 120mg 3-chloromethyl benzoic chloride was added then 100mg triethylamine was added dropwise over 2 minutes. The reaction was completed in half an hour. Product was extracted with ethyl acetate and washed with water. After the solvent was evaporated the residue was dissolved in 2ml 25 of N-methyl piperazine. This solution was stirred at  $60^\circ\text{C}$  for 2 hours and water was added. Product was extracted with ethyl acetate and washed with water. After solvent was evaporated, the residue was chromatographed on a column of silica gel to give **0136** 115mg Yield: 70%.  $^1\text{H}$  NMR (100 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  4.1(s, 2H), 6.7(s, 1H), 7.25(s, 5H), 7.6(d, 1H), 8.4(dd, 1H), 8.7(s, 1H), 8.9(d, 1H), 9.2(s, 1H).

Synthesis of **0137**. 100mg **0104** was dissolved in 40ml dry THF. While stirring thoroughly, 35 120mg 3-chloromethyl benzoic chloride was added, then 100mg triethylamine was added dropwise

over 2 minutes. The reaction was completed in half an hour. Product was extracted with ethyl acetate and washed with water. After the solvent was evaporated the residue was dissolved in 2ml morpholine. This solution was stirred at 60°C for 2 hours and water was added. Product was extracted with ethyl acetate and washed with water. After the solvent was evaporated, the residue 5 was chromatographed on a column of silica gel to give 0137 130mg Yield: 75%. <sup>1</sup>H NMR(100 MHz, CD<sub>3</sub>OD) δ2.4(s, 3H), 2.6(s, 8H), 3.6(s, 2H), 5.05(s, 2H), 6.5(s, 1H), 7.35(s, 5H), 7.4-8.0(multi, 4H), 8.2(s, 1H).

#### EXAMPLE 5. (Therapeutic Formulations)

10 In one aspect, the invention provides a variety of therapeutic uses for the types of dithioliopyrrolones and the specific compounds disclosed. In various embodiments, compounds of the invention may be used therapeutically in formulations or medicaments for the treatment of human proliferative diseases, such as blood vessel proliferative disorders, and fibrotic disorders such as cancers, tumors, hyperplasias, fibrosis, angiogenesis, psoriasis, atherosclerosis and smooth 15 muscle cell proliferation in the blood vessels, such as stenosis or restenosis following angioplasty, including cancers susceptible to compounds of the invention (such as susceptible solid tumors). The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a compound of the invention is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising compounds of the 20 invention and a pharmacologically acceptable excipient or carrier. The therapeutic composition may be soluble in an aqueous solution at a physiologically acceptable pH.

The invention provides pharmaceutical compositions (medicaments) containing (comprising) compounds of the invention. In one embodiment, such compositions include compounds of the invention in a therapeutically or prophylactically effective amount sufficient to alter, and preferably inhibit, pathological cellular proliferation (proliferative disease), and a 25 pharmaceutically acceptable carrier.

The compounds of the invention may be used in combination with other compositions and procedures for the treatment of diseases. For example, a tumor may be treated conventionally with photodynamic therapy, surgery, radiation or chemotherapy combined with a compounds of the 30 invention, and then compounds of the invention may be subsequently administered to the patient to extend the dormancy of micrometastases and to stabilize and inhibit the growth of any residue primary tumor.

A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as growth reduction or 35 elimination of a proliferative disease in the case of cancers. A therapeutically effective amount of a

compound of the invention may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the compound of the invention to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, a single bolus may be administered, several divided doses may be 5 administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.

Dosage unit form, as used herein, refers to physically discrete units suited as unitary dosages; each unit containing a predetermined quantity of active compound calculated to produce 10 the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for 15 the treatment of sensitivity in individuals. A therapeutically effective amount is also one in which any toxic or detrimental effects of the compound of the invention are outweighed by the therapeutically beneficial effects.

A "prophylactically effective amount" refers to an amount that is effective, at dosages and for the periods of time necessary, to achieve the desired prophylactic result, such as preventing or inhibiting the rate of metastasis of a tumour or the onset of intimal hyperplasia. A prophylactically 20 effective amount can be determined as described above for the therapeutically effective amount. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.

In particular embodiments, a preferred range for therapeutically or prophylactically effective amounts of a compounds of the invention may be 0.1 nM-0.1M, 0.1 nM-0.05M, 0.05 nM-25 15 $\mu$ M or 0.01 nM-10 $\mu$ M. Alternatively, the total daily dose may range from about 0.001 to about 1,000mg/kg of a patient's body mass. Dosage values may vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that dosage ranges 30 set forth herein are exemplary only and are not intended to limit the scope or practice of the methods of the invention.

As used herein "pharmaceutically acceptable carrier" or "diluent" or "excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. In one embodiment, 35 the carrier is suitable for parenteral administration. Alternatively, the carrier can be suitable for

intravenous, intraperitoneal, intramuscular, sublingual or oral administration. Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any 5 conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into the compositions.

Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a solution, microemulsion, 10 liposome, or other ordered structure suitable to high drug concentration. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of 15 surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride, and the like, in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, monostearate salts and gelatin. Moreover, the compounds of the invention can be administered in a time release formulation, for 20 example in a composition which includes a slow release polymer. The active compounds can be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid and polylactic, polyglycolic copolymers (PLG). 25 Many methods for the preparation of such formulations are patented or generally known to those skilled in the art.

Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by 30 incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

In accordance with an alternative aspect of the invention, a compound of the invention may be formulated with one or more additional compounds that enhance the solubility of the compound of the invention.

5 In accordance with another aspect of the invention, therapeutic compositions of the present invention, comprising compounds of the invention, may be provided in containers having labels that provide instructions for use of compounds of the invention to treat proliferative diseases, including cancers and psoriasis.

## CONCLUSION


10 Although various embodiments of the invention are disclosed herein, many adaptations and modifications may be made within the scope of the invention in accordance with the common general knowledge of those skilled in this art. Such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way. Numeric ranges are inclusive of the numbers defining the range.

15

## CLAIMS

## WHAT IS CLAIMED IS:

1. A compound of the formula shown below:




5 wherein  $Z =$  aryl, heterocyclic, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl group, while  $X$  and  $Y$  can be the same or different, are hydrogen, substituted or unsubstituted alkyl, cycloalkyl, aryl, aralkyl or heterocyclic group except the compounds with:

$Z =$  phenyl,  $Y = H$ ,  $X = H$ , methyl or benzyl, and  $Z = 4$ -pyridine,  $X =$  methyl,  $Y = H$ .

10 Or When  $X =$  aryl, heterocyclic,  $Y$  and  $Z$ , can be the same or different, are hydrogen, unsubstituted or substituted or alkyl of two or less hydroxyl groups and no carboxylic acid group, cycloalkyl, aryl, aralkyl or heterocyclic group, except the chemicals with:


$Z =$  methyl,  $Y = H$ ,  $X =$  phenyl, 4-methoxyphenyl, 4-methylphenyl.

2. A compound of claim 1, wherein

15  $Z =$   , wherein  $Z_1$  is a group with at least two hydrophilic atoms selected from N or O, such as piperazinyl, 4-methyl-piperazinyl and morpholinyl, while  $X$  and  $Y$  can be the same or different, are hydrogen, substituted or unsubstituted alkyl, cycloalkyl, aryl, aralkyl or heterocyclic group.

20 3. Use of a compound according to claim 1 in the manufacture of a medicament for the treatment or prophylaxis of proliferative diseases.

4. Use of a compound of the formula show below




wherein Z= phenyl, Y = H, X = H, methyl or benzyl; Z = 4-pyridine, X = methyl, Y =H; or Z = methyl, Y = H, X = phenyl, 4-methoxyphenyl or 4-methylphenyl in the manufacture of a medicament for the treatment or prophylaxis of proliferative diseases.

5 5. Use of a compound according to claim 2 in the manufacture of a medicament for the treatment or prophylaxis of proliferative diseases.

6. A pharmaceutical composition comprising a compound of the structure of claim 1 wherein Z = aryl, heterocyclic, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl group, while X and Y can be the same or different, are hydrogen, substituted or 10 unsubstituted alkyl, cycloalkyl, aryl, aralkyl or heterocyclic group or a pharmaceutically acceptable salt thereof, in association with a pharmaceutical carrier or diluent.

7. A pharmaceutical composition comprising a compound of the structure of claim 2 or a pharmaceutically acceptable salt thereof, in association with a pharmaceutical carrier or diluent.

15 8. A compound of the formula shown below:



wherein Z= methyl; Y = methyl; while X can be the same or different, is hydrogen, substituted or unsubstituted alkyl, cycloalkyl, aryl, aralkyl or heterocyclic group, except that when X is methyl Z is not methyl.

20 9. Use of a compound according to claim 8 in the manufacture of a medicament for the treatment or prophylaxis of proliferative diseases.

10. A pharmaceutical composition comprising a compound of the structure of claim 9 or a pharmaceutically acceptable salt thereof, in association with a pharmaceutical carrier or diluent.

(19) World Intellectual Property Organization International Bureau



22 SEP 2004



(43) International Publication Date  
2 October 2003 (02.10.2003)

PCT

(10) International Publication Number  
WO 2003/080624 A3

(51) International Patent Classification<sup>7</sup>: C07D 495/04, A61K 31/407, A61P 35/00, C07D 519/00

5551 Molina Road, North Vancouver, British Columbia V7R 4P3 (CA).

(21) International Application Number:  
PCT/CA2003/000380

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 18 March 2003 (18.03.2003)

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

Published:

— with international search report

(26) Publication Language: English

(88) Date of publication of the international search report:  
25 March 2004

(30) Priority Data:

60/367,265 26 March 2002 (26.03.2002) US  
60/418,698 17 October 2002 (17.10.2002) US

(71) Applicant (*for all designated States except US*):  
WELICHEM BIOTECH INC. [CA/CA]; 316-4475 Wayburne Drive, Burnaby, British Columbia V5G 3L1 (CA).


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): CHEN, Genhui [CA/CA]; 4573 Frances, Burnaby, British Columbia V5C 2R6 (CA). LI, Bin [CN/CA]; 4720 Pandora Street, Burnaby, British Columbia V5C 2C3 (CA). LI, Jianxiong [CA/CA]; 117 Buckingham Drive, Port Moody, British Columbia V3H 2T4 (CA). WEBSTER, John [CA/CA];

WO 2003/080624 A3

(54) Title: DITHIOLOPYRROLONE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISEASES



(57) Abstract: The present invention provides novel dithiopyrrolone compounds of Formula (I) and their salts, which are useful as treatment for cancer and other proliferative diseases. The present invention also provides therapeutic compositions comprising particularly useful types of dithiopyrrolones, the salts thereof, and methods of using the compounds within such types, particularly in treating proliferative diseases such as cancer.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/03/00380

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C07D495/04 A61K31/407 A61P35/00 C07D519/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, EMBASE, BEILSTEIN Data, PAJ, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 12543 A (CHEN GENHUI ;LI JIANXIONG (CA); WEBSTER JOHN MALCOLM (CA)) 18 March 1999 (1999-03-18) cited in the application Claims 1, 3-4, 10, 13, 16; compounds XN0, XN1, XN3;Table on p. 12 Figure 1	1-7
X	CELMER, WALTER D. ET AL: "A common hydrolysis product of thiolutin and aureothrinicin" ANTIBIOTICS ANN. 1953-54, PROC. SYMPOSIUM ANTIBIOTICS (WASH., D.C.), 1953, pages 622-625, XP009011765 Compounds (X) and (XI); p. 623, 1. 9-15 ----- -/-	1-7

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

18 June 2003

Date of mailing of the international search report

24.11.2003

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Rivat, C.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB93/00380

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2 173 499 A (ICI PLC) 15 October 1986 (1986-10-15) Claims 1, 4-6; formula (I); Table I, compounds 4-5, 12, 16, 22; example 1 -----	1, 6
X	PATENT ABSTRACTS OF JAPAN vol. 012, no. 358 (C-531), 26 September 1988 (1988-09-26) & JP 63 112586 A (NIPPON KAYAKU CO LTD), 17 May 1988 (1988-05-17) Formula (VI) abstract -----	1, 6
X	WO 94 28001 A (SMITHKLINE BEECHAM PLC ;BAGGLEY KEITH HOWARD (GB); BROOM NIGEL JO) 8 December 1994 (1994-12-08) Claims 1-2; formula (I) -----	1, 6
P, X	LAMARI L. ET AL.: "New Dithiopyrrolone Antibiotics from Saccharothrix sp. SA 233. I. Taxonomy, Fermentation, Isolation and Biological Activities" J. ANTIBIOTICS, vol. 55, no. 8, 2002, pages 696-701, XP009011640 Compounds 1 and 2 -----	1, 6

# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/ISA 03/00380

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple Inventions in this International application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-7 (all in part)

### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-7 (all in part)

Dithiopyrrolone derivatives substituted in 6-position by an (unsaturated hydrocarbon)carbonyl-amine and their use as antiproliferative agents

---

2. claims: 1-7 (all in part)

6-Amido-dithiopyrrolone derivatives substituted in 4-position by a cyclic moiety and their use as antiproliferative agents

---

3. claims: 8-10

6-Dimethylaminodithiopyrrolone derivatives and their use as antiproliferative agents

---

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9912543	A	18-03-1999	CA AU AU WO CN CN EP JP	2212237 A1 759990 B2 9057098 A 9912543 A1 1360891 A 1276723 T 1009401 A1 2001515861 T		05-03-1999 01-05-2003 29-03-1999 18-03-1999 31-07-2002 13-12-2000 21-06-2000 25-09-2001
GB 2173499	A	15-10-1986	AU DE FR JP ZA	5245986 A 3602148 A1 2590573 A1 61183290 A 8600175 A		07-08-1986 07-08-1986 29-05-1987 15-08-1986 29-10-1986
JP 63112586	A	17-05-1988	NONE			
WO 9428001	A	08-12-1994	AU WO EP JP ZA	6928294 A 9428001 A1 0699203 A1 8510265 T 9403452 A		20-12-1994 08-12-1994 06-03-1996 29-10-1996 16-05-1995